Many previous studies have demonstrated promising outcomes of anti-VEGF treatment for ROP, and the recurrence of ROP was reported in 4–83% patients (3, 16, 17), which may be influenced by the types of ROP and other demographic characteristics. This evidence concerns the gene VEGFA and retinopathy of prematurity.